Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics

Vertex Pharmaceuticals Incorporated (VRTX)

Today's Latest Price: $214.54 USD

5.97 (-2.71%)

Updated Oct 20 4:00pm

Add VRTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

VRTX Stock Summary

  • VRTX has a higher market value than 96.61% of US stocks; more precisely, its current market capitalization is $57,435,651,820.
  • In terms of twelve month growth in earnings before interest and taxes, Vertex Pharmaceuticals Inc is reporting a growth rate of 158.49%; that's higher than 92.05% of US stocks.
  • The volatility of Vertex Pharmaceuticals Inc's share price is greater than that of only 6.43% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Vertex Pharmaceuticals Inc, a group of peers worth examining would be MU, AMAT, LRCX, EA, and XLNX.
  • VRTX's SEC filings can be seen here. And to visit Vertex Pharmaceuticals Inc's official web site, go to

VRTX Stock Price Chart Interactive Chart >

Price chart for VRTX

VRTX Price/Volume Stats

Current price $214.54 52-week high $306.08
Prev. close $220.51 52-week low $174.82
Day low $214.48 Volume 2,924,700
Day high $222.62 Avg. volume 1,815,490
50-day MA $264.36 Dividend yield N/A
200-day MA $259.28 Market Cap 55.88B

Vertex Pharmaceuticals Incorporated (VRTX) Company Bio

Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.

VRTX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$214.54$44312.91 19996%

Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 97th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 20094.5%; returns of such proportions should be viewed with some skepticism, though. The most interesting components of our discounted cash flow analysis for Vertex Pharmaceuticals Inc ended up being:

  • In the past 3.75 years, Vertex Pharmaceuticals Inc has a compound free cash flow growth rate of 2.59%; that's better than 93.01% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 4.95% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 53.34% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Vertex Pharmaceuticals Inc? See KMDA, ASNB, GEN, AMEH, and AMRX.

VRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

VRTX Latest Social Stream

Loading social stream, please wait...

View Full VRTX Social Stream

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators

BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA

Business Wire | September 24, 2020

Crispr: The Frontier Of Gene Editing

The greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow far more than the industry as a whole. - Phillip Fisher (Warren Buffett's mentor asides from Ben Graham) As you can see, biotech is a lucrative...

BioSci Capital Partners on Seeking Alpha | September 18, 2020

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

Thinking about buying stock in Delta Air Lines, Scientific Games, GameStop, Vertex Pharmaceuticals, or Fortress Biotech?

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, SGMS, GME, VRTX, and FBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | September 14, 2020

Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO®* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible

Business Wire | September 14, 2020

Read More 'VRTX' Stories Here

VRTX Price Returns

1-mo -18.73%
3-mo -24.58%
6-mo -20.50%
1-year 12.29%
3-year 38.74%
5-year 87.58%
YTD -2.01%
2019 32.13%
2018 10.58%
2017 103.42%
2016 -41.45%
2015 5.92%

Continue Researching VRTX

Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:

Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7145 seconds.